NasdaqCM - Nasdaq Real Time Price USD

RedHill Biopharma Ltd. (RDHL)

0.4571 -0.0029 (-0.63%)
At close: 4:00 PM EDT
0.4600 +0.00 (+0.63%)
After hours: 6:03 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Dror Ben-Asher Co-Founder, Chairman & CEO 594.61k -- 1966
Mr. Razi Ingber Chief Financial Officer 339.82k -- 1984
Mr. Gilead Raday MPhil, MSc Chief Operating Officer 365.56k -- 1975
Mr. Adi Frish Chief Corporate & Business Development Officer 339.3k -- 1970
Mr. Rick D. Scruggs Chief Commercial Officer, President of RedHill Biopharma Inc. & Director 469.8k -- 1960
Ms. Alexandra Okmian Senior Business Development & Investor Relations Manager -- -- --
Dr. Reza Fathi Ph.D. Senior Vice President of Research & Development 299.29k -- 1955
Mr. Guy Goldberg J.D. Chief Business Officer 338.13k -- 1976
Dr. June S. Almenoff FACP, M.D., Ph.D. Chief Medical Officer -- -- 1957
Ms. Patricia Anderson B.Sc. RAC Senior Vice President of Regulatory Affairs -- -- --

RedHill Biopharma Ltd.

21 Ha’arba’a Street
Tel Aviv, 6473921
Israel
972 3 541 3131 https://www.redhillbio.com
Sector: 
Healthcare
Full Time Employees: 
53

Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Corporate Governance

RedHill Biopharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • May 06, 2024
    6-K: Corporate Changes & Voting Matters
    See Full Filing
  • Apr 24, 2024
    6-K: Corporate Changes & Voting Matters
    See Full Filing
  • Apr 18, 2024
    POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
    See Full Filing
  • Apr 08, 2024
    20-F: Periodic Financial Reports
    See Full Filing
  • Apr 04, 2024
    6-K: Corporate Changes & Voting Matters
    See Full Filing

Upcoming Events

Jun 10, 2024 - Jun 14, 2024
RedHill Biopharma Ltd. Earnings Call

Related Tickers

KMDA Kamada Ltd.
5.66
+2.35%
 
SBFM Sunshine Biopharma, Inc.
0.8995
+3.26%
 
AKAN Akanda Corp.
0.0880
-4.97%
 
SBFMW Sunshine Biopharma, Inc.
0.1800
+36.05%
 
OPTN OptiNose, Inc.
1.1300
-3.42%
 
IMCC IM Cannabis Corp.
0.7151
+0.85%
 
EBS Emergent BioSolutions Inc.
5.08
-5.22%
 
SXTC China SXT Pharmaceuticals, Inc.
1.1100
+6.73%
 
BFRI Biofrontera Inc.
1.2900
+9.32%
 
ALKS Alkermes plc
24.49
-0.89%